CA-MANSCAPED
22.10.2020 15:02:07 CEST | Business Wire | Press release
Male grooming. In this day and age, these two words can - and should - mean trimming and tidying up all areas of a man’s body, including the nether regions. You may have thought about it, or even partaken in this all-important activity and reaped the results! But was it as enjoyable as it was effective? And, more importantly, were you equipped with the right tools for the job?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005418/en/
If you are not already familiar with the pioneer below-the-waist grooming and hygiene brand , let us formally introduce you to MANSCAPED™ . This California-based startup has single-handedly disrupted the men’s grooming industry and created a completely new category in the consumer packaged goods space.
Born in 2016, the booming direct-to-consumer (DTC) company designs and develops premium products for groin and body grooming , while upholding a steadfast mission to empower the modern man to unabashedly grab ahold of his situation “down there”. We are proud to report that since inception, the stigma-shattering brand has utterly taken off.
Today, MANSCAPED announces its latest and most extensive expansion yet into the European Union , which augments its reach to 1 billion people worldwide . This follows successful international launches earlier this year into Canada, Australia, New Zealand, and the United Kingdom. With the holidays on the horizon, the perfect present or self-care treat is now just a click away for every lady and gentleman in more than 30 countries worldwide .
“Entering into Europe in one fell swoop is no small feat, but we’re confident we have the infrastructure and high-powered passion to fuel this momentous launch,” said Stephanie Hinze, MANSCAPED’s Senior Director of International Operations. “Sharing the European Union’s values of inclusion and non-discrimination, we believe our trusted brand and superior products have sparked a new era of well-being for all and will continue to propel a movement throughout the region. We’re particularly excited to have laid the groundwork just in time for the holiday season in order to offer only the best tools and formulations to so many more men and women throughout the world.”
If that news doesn’t excite consumers enough, this milestone is coupled with a new product launch that our international fans have been waiting for. That’s right, our very first above-the-waist tool * is now available in over 30 countries! Combine this groundbreaking device with our best-selling below-the-waist trimmer and skincare products, and you have a set of essentials that is a must-have for the men on your list...
Introducing The Performance Package , our newest luxury grooming kit that includes:
The Lawn Mower™ 3.0 - The legendary electric trimmer for the groin and body is the cornerstone of a refined grooming routine. The precision engineered device boasts a 7,000 RPM motor with QuietStroke™ technology and replaceable ceramic blade with MANSCAPED’s SkinSafe™ technology that helps reduce the risk of nicks, cuts, and snags. The 600mA Li-Ion rechargeable battery and waterproof ergonomic design allows for a safe and easy trimming session.
*The Weed Whacker™ - Now Available Internationally - This revolutionary electric ear and nose hair trimmer is a technological masterpiece, redesigning the traditional nose hair taming tool by focusing on maximum performance and comfort, and offering a sleek, ultramodern design. The tool features SkinSafe technology, a 9,000 RPM motor and 360-degree rotary dual-blade system, and intelligently contoured design.
Crop Preserver™ - Ball deodorant is a thing, and it’s life-changing. The anti-chafing formula is infused with cooling aloe vera and controls any stench coming from an unwanted “swamp crotch”.
Crop Reviver™ - This innovative ball toner is the solution for maintaining hygiene and cleanliness on-the-go. The restorative spray relieves high-friction areas and post-shave irritation with just a spritz or two.
As a leading DTC brand, MANSCAPED offers a one-stop-shop online where customers can browse the full collection and purchase items a la cart or as part of a bundle - all with guaranteed free shipping. For our new consumers residing in Europe, please visit eu.manscaped.com to learn more and join the MANSCAPED Movement today!
About MANSCAPED™:
Founded in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple and effective male grooming routine. MANSCAPED offers direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, and the European Union. Retail placement includes Target and Best Buy locations throughout the U.S., with further retail availability coming soon. MANSCAPED.com is a one-stop shopping destination for men looking for a brand that is focused on the needs of what has, for too long, been a sensitive and often taboo subject. For more information, visit the website or follow on Facebook , Instagram , Twitter , TikTok , YouTube , and Triller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005418/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom